

Gemini Stock Analysis Report

Okay, I'm ready to analyze the provided SUNPHARMA.NS report and provide a trade recommendation.

Step 1: Audit the Data

- **Data Present:** Daily price chart, EMA crossover analysis, Bollinger Bands analysis, Supertrend analysis, MACD summary, Volatility Squeeze analysis, RSI-Volume divergence analysis, long-term and short-term fundamental analysis, and relative strength analysis.
- **Data Missing:** Weekly/Monthly price charts, in-depth volume analysis beyond the RSI-volume divergence. There is no information on the current sector/market conditions and competitor analysis.
- **Confidence Level:** Medium. The report offers various technical indicators and some fundamental metrics. However, the absence of longer-term charts, in-depth volume analysis, and broader market context limits the confidence in the analysis.

Step 2: Analyze the Setup

- **Price Structure:** The 3-year daily chart shows a clear uptrend, the stock has been rising steadily with some pullbacks.
- **Trend Direction:**
 - **EMA Crossover:** The stock has a Golden Cross (20-day EMA above 200-day EMA) indicating strong uptrend.
 - **Supertrend:** Indicates a DOWNTREND (Sell) signal, conflicting with EMA's uptrend indication.
- **Momentum:**
 - **MACD:** The MACD line is below the signal line, which is a bearish signal.
 - **RSI:** The RSI of 42.49 is a neutral indication.
 - **Relative Strength:** The stock is a Weakening Leader, with weakening strength.
- **Volatility:**
 - **Bollinger Bands:** The stock is below the lower band which indicates a possible buy (if using the inverse rule).
 - **Volatility Squeeze:** There is volatility squeeze activity which is a mixed signal. Usually, the volatility will expand to one side, however, its direction is difficult to forecast.
- **Fundamentals:**
 - **Long Term:** Growing on all metrics.
 - **Short Term:** Net Income and ROE is declining.

Step 3: Formulate the Recommendation

Given the mixed signals from both technical and fundamental indicators, and the limited data, **I recommend NO entry at this time.**

Here's why:

- **Conflicting Trend Signals:** The EMA crossover suggests an uptrend while the Supertrend indicates a downtrend. This lack of alignment is concerning.
- **Weakening Momentum:** **Bearish** MACD and "Weakening Leader" classification are concerning.
- **Fundamental Deterioration:** Short-term declining Net Income and ROE hint at potential near-term struggles.

Conditional Plan (If you are inclined to enter the stock)

Consider a conditional buy plan to increase confidence in the setup. This plan should be executed after the following.

Gemini Stock Analysis Report

- **Condition to Buy:**

- A decisive breakout above the Supertrend value of 1832.41, confirmed by a higher-than-average volume.
- MACD crosses above the signal line.
- Net income and ROE to be positive next quarter.
- **Entry Price:** A confirmed break above 1832.41
- **Stop Loss:** A hard stop at 1744.90 (the current price).
- **Take Profit:** Aim for a target of 1980 (approximately 8% upside).

Rationale:

This conditional plan waits for clear confirmation of a continued uptrend, which can be confirmed by a break of the super trend, EMA crossover, and positive quarterly results. These indicators offer the signal that an upwards rally has been established.

Disclaimer:

This analysis is based solely on the provided report and information, and the recommendations are based on my understanding of the information provided. Trading involves risks, and you are solely responsible for your investment decisions.

News & Analyst Targets

Okay, I will act as a stock research analyst and look for the latest information on Sun Pharmaceutical Industries (SUNPHARMA) to answer your questions.

Here's a summary of the latest news and information on Sun Pharmaceutical Industries (SUNPHARMA):

1. Latest News for SUNPHARMA this week (December 15 - December 20, 2025):

- **US FDA Inspection of Baska Facility:** Shares of Sun Pharma fell after the US FDA flagged its Baska manufacturing facility with an "Official Action Indicated" (OAI) status following an inspection conducted from September 8 to September 19, 2025. The OAI classification indicates that the FDA requires corrective action at the facility. However, Sun Pharma stated that it will continue to manufacture and supply approved products to the US market and is working with the FDA to achieve full compliance.
- **Delhi High Court Ruling on Semaglutide:** The Delhi High Court allowed Sun Pharma to manufacture its version of the diabetes and anti-obesity drug semaglutide for export. However, it restrained domestic sales until March 2026, when Novo Nordisk's secondary patent expires.

2. Brokerage Upgrades or Downgrades for SUNPHARMA:

- **August 2025 Downgrade:** Bank of America Securities downgraded Sun Pharma to "underperform" from "neutral," citing risks to premium valuations and slower-than-expected execution in specialty drugs. They also lowered the target price to Rs 1,570 from Rs 1,730.
- **October 2024 Downgrade:** MarketsMOJO downgraded Sun Pharmaceuticals Industries to 'Hold' due to its high valuation, even though the company has a healthy financial position.

3. Other News Impacting SUNPHARMA:

- **Q2 FY26 Results:** Sun Pharma reported strong Q2 FY26 results with a consolidated net profit of INR

Gemini Stock Analysis Report

- 3,118 crore (up 2.5% YoY) and revenue from operations of INR 14,478 crore (up 9% YoY).
- Illumya Launch in India:** Sun Pharma introduced Illumya in India for treating moderate-to-severe plaque psoriasis.
- Technical Breakout:** Sun Pharmaceuticals Ltd. has broken out of a falling trendline resistance on weekly charts, signaling potential for higher prices. Experts suggest a target of Rs 1,990 in 2-4 months, with a stop loss below Rs 1,690.

4. Analyst Targets for SUNPHARMA:

Here's a table summarizing the latest analyst target prices:

Metric	Value (INR)
Average Target Price	1,950.68
High Price Target	2,450.00
Low Price Target	1,570.00

- Consensus:** The consensus rating for Sun Pharma is "Buy" based on the input from analysts.
- Upside Potential:** The stock has a potential upside of approximately 11.79% based on the average analyst price target.
- Analyst Recommendations:** Out of analysts covering the stock, a majority recommend buying, while a smaller number suggest selling or holding.


Stock Detailed Analysis Report

SUNPHARMA.NS

Current Price: ₹1744.90

Generated: 2025-12-20 20:44

SUNPHARMA.NS - 3 Year Daily Price Chart



Long-term Fundamental Analysis (4 Years)

Metric	Is Growing?	Accelerating?	1Y Growth	3Y CAGR
Revenue	Yes	No	8.97%	10.64%
Net Income	Yes	No	14.12%	49.47%
ROE	Yes	No	0.61%	30.45%
EPS	Yes	No	14.29%	49.67%

Short-term Fundamental Analysis (6 Quarters)

Metric	Is Growing?	Recent QoQ	Avg QoQ
Revenue	Yes	7.57%	2.54%
Net Income	No	5.99%	-4.31%
ROE	No	-32.32%	-32.32%
EPS	Yes	-4.72%	1.45%

SUNPHARMA.NS - Relative Strength Analysis

== OVERVIEW ==:

Benchmark Index:	^CNXPHARMA
Sector:	Pharma
Classification:	Weakening Leader
RS Score:	49.8/100
:	

== RS RATIOS ==:

1M RS:	0.979 [Neutral]
3M RS:	1.045 [Leader]
6M RS:	0.988 [Neutral]
1Y RS:	0.950 [Neutral]
:	


== TURNAROUND ANALYSIS ==:

Turnaround Status:	Not Detected
:	


SIGNAL CRITERIA::

✗ Emerging RS:	Not accelerating
✓ Medium-term Lagging:	6M=0.988, 1Y=0.950 (≤ 1.0)
✓ Performance Improving:	3M (+5.4%) > 6M (+4.8%)


Relative Strength Analysis: SUNPHARMA.NS vs ^CNXPHARMA
Classification: Weakening Leader
Price Performance Comparison (Normalized)



RS Ratio Trends (Multiple Timeframes)



RS Composite Score Timeline



SUNPHARMA.NS - EMA Crossover Summary

EMA 20:	1778.12
EMA 50:	1746.37
EMA 200:	1701.94
Trend Status:	Strong Uptrend
Golden Cross Date:	2025-11-18 00:00:00
Golden Cross Price:	1758.80


SUNPHARMA.NS EMA Crossover Analysis



SUNPHARMA.NS - Bollinger Bands Summary

Current Price:	1744.90
Upper Band:	1836.18
Middle Band (SMA 20):	1793.11
Lower Band:	1750.03
%B:	-0.0595
Band Width:	0.0480
Status:	Below Lower Band
Signal:	None
Recent Signal 1:	Sell Signal at 2025-12-01 00:00:00

SUNPHARMA.NS Bollinger Bands (20, 2) Analysis




SUNPHARMA.NS - Supertrend Summary

Status: DOWNTREND (Sell)

Supertrend Value: 1832.41

Signal Identified On: 2025-12-18

Supertrend Analysis for SUNPHARMA.NS (Period: 14, Multiplier: 3.0, Interval: 1d)




SUNPHARMA.NS - MACD Summary

MACD Line:	6.35
Signal Line:	16.41
Histogram:	-10.06
Trend:	Bearish
Momentum:	Strengthening
Signal:	None

SUNPHARMA.NS Price




SUNPHARMA.NS MACD (12, 26, 9)



SUNPHARMA.NS - Volatility Squeeze Summary

BB Width:	0.0480
ATR:	27.2714
Total Signals:	24
Signal 1:	ATR Contraction at 2025-11-27 00:00:00 (Price: 1810.30)
Signal 2:	ATR Contraction at 2025-11-28 00:00:00 (Price: 1831.60)
Signal 3:	ATR Contraction at 2025-12-02 00:00:00 (Price: 1799.50)
Signal 4:	BB Squeeze at 2025-12-16 00:00:00 (Price: 1781.30)
Signal 5:	BB Squeeze at 2025-12-17 00:00:00 (Price: 1792.90)

SUNPHARMA.NS - Volatility Squeeze Analysis



SUNPHARMA.NS - RSI-Volume Summary

Current RSI:	42.49
Current Volume:	2768986
Volume MA 20:	2115961
Bullish Divergences:	1
Bearish Divergences:	3
Bullish Div 1:	Date: 2025-06-04 00:00:00, Price: 1664.90
Bearish Div 1:	Date: 2024-04-01 00:00:00, Price: 1629.25
Bearish Div 2:	Date: 2025-07-30 00:00:00, Price: 1733.80

SUNPHARMA.NS RSI-Volume Divergence Analysis

